1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
SkinBioTherapeutics Plc

SkinBioTherapeutics Plc

LLSE:SBTX
6.00
GBX
0.00
(0.00%)
4.08BMarket Cap
Dec 02Next Earn
SkinBioTherapeutics Plc
LSE:SBTX
(London Stock Exchange)

Recent

price

6.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
GBP
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.02
- -
Revenue per Share
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
- -
- -
Basic EPS, GAAP
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.04
0.03
0.03
0.02
0.03
0.02
0.01
0.01
0.04
0.03
Book Value per Share
- -
0.03
0.03
0.03
0.02
0.03
0.01
0.01
- -
0.02
0.01
Tangible Book Value per Share
119
58
119
122
128
147
157
165
186
228
259
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
5
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-3,631.57
-2,237.77
-244.47
-24.06
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
-1
-2
-1
-3
-3
-3
-1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-3,735.37
-2,146.91
-237.95
-15.01
- -
Profit Margin (%)
- -
4
3
3
2
5
2
1
- -
6
4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
LT Debt
- -
4
3
4
2
5
2
2
3
9
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-28.05
-22.06
-31.67
-47.8
-37.31
-72.62
-126.84
-115.86
-11.24
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
228
259
259
Market Capitalization
42
43
41

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
3
7
5
Cash, Cash Equivalents & STI
1
5
3
Accounts Receivable, Net
1
1
1
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.11%
217.15%
Free Cash Flow
- -
18.39%
-52.34%
Net Income, GAAP
- -
3.52%
-75.79%
Sales/Revenue/Turnover
- -
- -
283.74%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
5
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.02
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
SkinBioTherapeutics Plc (SBTX.L) develops and commercialises microbiome-based therapeutics and skincare products targeting skin diseases and conditions; its core offerings include SkinBiotix®, a platform featuring bacteriotherapy products such as FlaxSeedSFI for atopic dermatitis treatment, alongside cosmetic and over-the-counter skincare lines like AxisBiotix® for microbiome balance and hydration. The company operates primarily in the biotechnology and personal care sectors, serving dermatology patients, skincare consumers, and healthcare providers through clinical-stage development and commercial distribution. Founded in 2015 and headquartered in York, United Kingdom, it focuses on the UK and European markets with expansion into international dermatology and cosmetics channels. Recent developments include a strategic research collaboration with Croda International Plc announced in 2024 to advance microbiome-based cosmetic ingredients, alongside progression of its Phase II clinical trial for FlaxSeedSFI in mild atopic dermatitis patients, with topline data expected in late 2025; the company also secured additional grant funding from Innovate UK in early 2025 to support platform expansion and completed a successful retail launch of its first OTC skincare product line in the UK during 2024.